Introduction
The lymphatic vascular system is involved in many pathological processes, including lymphedema and the metastatic spread of cancer. Despite the importance of the lymphatic system for human health, our knowledge of lymphatic vessel development lags considerably behind that of blood vascular development, and it is only in recent years that some of the molecules that regulate lymphangiogenesis have been identified (for review see Tammela et al., 2005) . The data presented in this study establish the transcription factor TBX1 as a new player in lymphangiogenesis.
TBX1 encodes a T box transcription factor involved in the 22q11 deletion syndrome (22q11DS), also known as DiGeorge syndrome. 22q11DS patients have a complex phenotype that includes cardiovascular defects, craniofacial dysmorphism, hypocalcemia, immune deficiency, behavioral disorders, and psychiatric diseases. Most of the physical abnormalities are caused by TBX1 haploinsufficiency (Yagi et al., 2003) , and we have shown that TBX1 may contribute to the psychiatric disorders (Paylor et al., 2006) . Lymphatic defects have not been reported in 22q11DS patients, with a single exception (Mansir et al., 1999) . However, the recurrent infections associated with the disease may be contributed by subtle lymphatic abnormalities in addition to the known T cell immune deficiency.
In the mouse, mutation of Tbx1 recapitulates the common physical abnormalities seen in patients (Jerome and Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001) . During mouse development, Tbx1 is widely expressed in the developing pharynx, ear, and the endothelial lining of some blood vessels (Vitelli et al., 2002; Paylor et al., 2006) . Intriguingly, a L ymphatic dysfunction causes several human diseases, and tumor lymphangiogenesis is implicated in cancer spreading. TBX1 is the major gene for DiGeorge syndrome, which is associated with multiple congenital anomalies. Mutation of Tbx1 in mice recapitulates the human disease phenotype. In this study, we use molecular, cellular, and genetic approaches to show, unexpectedly, that Tbx1 plays a critical role in lymphatic vessel development and regulates the expression of Vegfr3, a gene that is essential for lymphangiogenesis. Tbx1 activates Vegfr3 transcription in endothelial cells (ECs) by binding to an enhancer element in the Vegfr3 gene. Conditional deletion of Tbx1 in ECs causes widespread lymphangiogenesis defects in mouse embryos and perinatal death. Using the mesentery as a model tissue, we show that Tbx1 is not required for lymphatic EC differentiation; rather, it is required for the growth and maintenance of lymphatic vessels. Our findings reveal a novel pathway for the development of the lymphatic vessel network.
Tbx1 regulates Vegfr3 and is required for lymphatic vessel development
A similar pathology has been reported in several mouse mutants that have mutations in genes involved in lymphatic vessel development (for review see Tammela et al., 2005) , suggesting that Tbx1 may be required in ECs for lymphangiogenesis. In view of the dramatic phenotype seen in Tie2-Cre; Tbx1 flox/lacz mutants, we first evaluated lymphangiogenesis in the gastrointestinal (GI) tract of preterm embryos. For this, we performed immunostaining on isolated GI tracts of E18.5 embryos using antibodies against three EC-specific genes, CD31 (Pecam-1), Vegfr3, and Lyve1. Anti-Pecam-1 identifies ECs of arteries, veins, and lymphatic vessels, whereas anti-Vegfr3 and antiLyve1 are specific for lymphatic ECs (LECs) at this embryonic stage. Anti-Pecam-1 revealed an overall reduction in the number of vessels in the mesentery of both Tie2-Cre; Tbx1 flox/lacz mutants (Fig. 1, B and B) and Tbx1 lacz/lacz (null) mutants (not depicted). We used anti-Vegfr3 to confirm that the missing vessels were indeed lymphatic vessels (Fig. 1, C and C) . Similar results were obtained with anti-Lyve1 (Fig. S1 ), thereby confirming that the lack of staining with anti-Vegfr3 was caused by the absence of the lymphatic vessels. Thus, EC-specific loss of Tbx1 causes a developmental failure of the entire GI lymphatic vasculature.
variety of vascular abnormalities has been reported in 22q11DS patients (D'Antonio and Marsh, 1987; MacKenzie-Stepner et al., 1987; Mansour et al., 1987) . In this study, we sought to establish the requirement for Tbx1 in endothelial cells (ECs) and found an unexpected and critical role in lymphatic vessel development.
Results and discussion

Loss of Tbx1 in ECs causes perinatal lethality and lymphatic abnormalities
We deleted Tbx1 specifically in ECs using an EC-specific Cre driver, Tie2-Cre (Kisanuki et al., 2001 ). We crossed Tie2-Cre; Tbx1 lacz/+ mice with Tbx1 flox/flox mice and genotyped 114 offspring at weaning. We did not recover any Tie2-Cre; Tbx1 flox/lacz pups (i.e., null for Tbx1 in ECs and heterozygous in all other tissues). In contrast, this genotype was recovered at the normal Mendelian ratio (10/39) on embryonic day (E) 18.5. We established that Tie2-Cre; Tbx1 flox/lacz mutants died between postnatal day (P) 2 and 4, when they showed growth failure, dehydration, and abdominal chylous ascites ( Fig. 1 A) , which are features that were not present in controls (Fig. 1 A) . used a lacZ reporter allele (Lindsay et al., 2001 ) and an antiTbx1 antibody. At E13.5, we identified -galactosidase (-gal) activity in the proximal mesentery, where it colocalized with anti-Vegfr3 immunostaining (Fig. 2, A and B) , indicating that Tbx1 is expressed in the LECs of early mesenteric lymphatic vessels. Note that Tbx1 expression was not LEC specific at this or later embryonic stages, as -gal activity was also identifiable in some ECs of the mesenteric artery and vein. Robust -gal activity in lymphatic vessels continued through E16.5 (Fig. 2, C, D, and F) . Anti-Tbx1 immunostaining showed a similar pattern of expression (Fig. 2 E) . We determined the time requirement for Tbx1 in mesenteric lymphangiogenesis using transgenic mice that carry a tamoxifen (TM)-inducible Cre recombinase under the control of a ubiquitous promoter (TgCAGG-CreER TM ; Hayashi and McMahon, 2002 constituted the control group. Embryos were collected at E18.5, and intestines were immunostained with anti-Vegfr3. In control embryos exposed to TM at E11.5, the mesenteric lymphatics We next examined lymphatic vessels in other tissues, including heart, diaphragm, and skin in Tbx1 lacz/+ and Tbx1 lacz/lacz embryos at E18.5 (Fig. S2 ). In the heart, anti-Vegfr3 immunostaining revealed a severe reduction in the number of lymphatic vessels in Tbx1 lacz/lacz embryos, with only a few vessels adjacent to the aorta being identifiable (Fig. S2 , A-B). Anti-Pecam-1 immunostaining showed similar staining patterns in both genotypes (Fig. S2 , C and C), although in Tbx1 lacz/lacz embryos, some vessels were dilated, and there was a reduced vessel density. In the diaphragm, an extensive network of lymphatic vessels was observed in control embryos (Fig. S2 , D and E), whereas in Tbx1 lacz/lacz embryos, this network was severely reduced (Fig. S2 , D and E). Similar results were obtained with antiLyve1 (Fig. S2 , F and F). In the skin, Tbx1 lacz/lacz embryos had fewer subcutaneous lymphatic vessels than control embryos (Fig. S2, G and H and G and H, respectively) . Consistent with this observation, Tbx1 lacz/lacz embryos showed subcutaneous edema at E14.5 (Fig. S2, I and I).
Tbx1 is required early in mesenteric lymphangiogenesis
Because of the severity of the mesenteric phenotype, we focused our attention on the function of Tbx1 in this tissue. In the mouse, the first mesenteric lymphatic vessels form around E13 (van der Putte, 1975; Kim et al., 2007) . To monitor Tbx1 expression, we were seen (Fig. S3 C, arrows) . Induction at E14.5 resulted in apparently normal lymphatic vessel development at E18.5 (Fig. S3 D) . Thus, Tbx1 is required for lymphangiogenesis until E14. In the mouse, this is 24 h after the onset of mesenteric lymphangiogenesis (van der Putte, 1975) . As shown in Fig. 2 (A and B), Tbx1 is expressed in mesenteric LECs at this critical stage.
Tbx1 is required for lymphatic vessel maintenance
We asked whether Tbx1-deficient lymphatic vessels form, and if so, what their fate is. To address this, we used two previously characterized Tbx1-null alleles, Tbx1
E5 (Xu et al., 2004) and Tbx1 Cre (Huynh et al., 2007) , in conjunction with the Cre reporter R26R (Soriano, 1999) . X-gal staining of isolated intestines at E14.5 shows extensive contribution of Tbx1-traced cells to the mesenteric vessels of control (Tbx1 Cre/+ ; R26R) embryos (Fig. 3 A) and null mutant (Tbx1
Cre/E5
; R26R) embryos (Fig. 3 A) . Double staining (X-gal and anti-Lyve1) of Tbx1
Cre/+ ; R26R embryos at E14.5 (Fig. 3 B) and E15.5 (Fig. 3 C) revealed that the mesenteric lymphatic endothelium is largely composed of Tbx1-traced cells (Fig. 3, black 
arrowheads). In Tbx1
Cre/E5
; R26R embryos (Fig. 3 , B and C), Tbx1-traced cells contributed to clusters of vessels (Fig. 3 , B and C, red arrowheads) that were unlike the characteristic network of lymphatic vessels seen in controls. Nevertheless, some of these abnormal vessels were Lyve1 + , indicating their lymphatic nature. In the distal mesentery, -gal + vessels were Lyve1 negative (Fig. 3, D and D) and are likely tributaries of the mesenteric artery and vein (note that the punctate brown signals in mutant and control sections are Lyve1 + macrophages). Thus, Tbx1 is not essential for mesenteric lymphatic vessel formation. We determined the fate of the abnormal lymphatic vessels at later embryonic stages. At E16.5, only a few -gal + vessels were identifiable in the proximal mesentery of Tbx1 Cre/E5 ; R26R embryos (Fig. 3 E) , some of which were also Lyve1 + (Fig. 3 E, red arrowhead), whereas in the distal mesentery, -gal + vessels were Lyve1 negative, as seen at E15.5 (not depicted). At E18.5, -gal + vessels were Lyve1 negative and had the anatomy of veins and arteries (unpublished data). Similar results were obtained at the aforementioned embryonic stages with anti-Vegfr3 (unpublished data). Thus, on a Tbx1-null background, the mesenteric lymphatic vessels form, but they are abnormal, they fail to extend into the distal mesentery, and between E15.5 and E16.5, they are almost completely lost. To determine whether this loss is caused by cell death, we performed anti-caspase 3 immunostaining on isolated GI tracts of Tbx1 lacZ/+ and Tbx1 lacZ/lacZ embryos at E14.5 and E16.5. Results showed a significant increase in the number of apoptotic cells adjacent to the mesenteric artery of Tbx1 lacZ/lacZ embryos (P < 0.01) at E16.5 (Fig. S3 , F-G) but not at E14.5 (Fig. S3, E , E, and G).
Tbx1 regulates transcription of growth factors and angiogenic markers in ECs
We next used quantitative real-time PCR (qRT-PCR) to explore the transcriptional response of 82 genes involved in angiogenesis and lymphangiogenesis (RT 2 Profiler PCR Array; QIAGEN) to TBX1 expression in cultured human umbilical vein ECs developed normally (Fig. S3 A) . In contrast, TgCAGG-CreER TM ; Tbx1 flox/lacz mutants exposed to TM at E11.5 (Fig. S3 B) lymph sacs and in subcutaneous lymphatic vessels (unpublished data), both of which are present in Tbx1 / mutants, although they are abnormal and reduced in number.
Therefore, we focused our attention on VEGFR3, which is essential for lymphangiogenesis (Karkkainen et al., 2000 (Karkkainen et al., , 2001 and is regulated by TBX1 in a dose-dependent manner (Fig. 4 A) . Because HUVECs express endogenous TBX1, we knocked it down using siRNA to test whether VEGFR3 expression responds to it. We obtained an 80% reduction in TBX1 expression and a 40% reduction in VEGFR3 expression in multiple experiments (Fig. 4 I) . Similar experiments performed on cultured human microvascular LECs (HMLECs) yielded a 60% reduction in VEGFR3 expression (Fig. 4 J) . siRNA knockdown of TBX1 mRNA resulted in reduced TBX1 protein expression in both HMLECs (Fig. 4 K) and in HUVECs (not depicted).
To identify putative TBX1-responsive enhancers within the VEGFR3 gene, we searched for evolutionarily conserved DNA segments containing conserved T box-binding elements (TBE). A 1.1-kb segment was identified that encompassed intron 11-12 and contained a single TBE. We cloned this DNA fragment from the mouse genome and named it In 11-12TBE . We asked whether the In 11-12TBE enhancer responds to Tbx1 in a tissue culture system. To test this, we cotransfected JEG3 cells with a Tbx1 expression vector and a luciferase reporter containing In 11-12TBE and a basal promoter (Fig. 5 A) . Overexpression of Tbx1 led to a fourfold increase in luciferase activity in multiple experiments (Fig. 5 B) . In contrast, mutation of TBE (HUVECs). Among the markers of lymphangiogenesis, PROX1 and LYVE1 did not change significantly in response to TBX1 transfection. However, VEGFR3, PDPN, and VEGFD increased significantly, as did IGF1 (Fig. 4 A) . We validated data obtained by qRT-PCR and immunocytofluorescence with VEGFD and IGF1 antibodies on TBX1-transfected HUVECs (Fig. 4, B-E) . Results showed that 7% of the control cell population expressed VEGFD or IGF1 protein, and this percent increased two-to threefold after TBX1 transfection (Fig. 4 F) . This suggests that at least part of the increased level of mRNA encoding those proteins is caused by an increase in the number of cells expressing those markers. We evaluated cell proliferation by immunocytofluorescence with anti-phosphohistone H3. In HUVECs transfected with 3 µg human TBX1 expression vector, cell proliferation increased >1.8-fold above that of control cultures (Fig. 4 G) . We used Western blotting to confirm that transfection of HUVECs with the TBX1-expressing vector resulted in increased expression of TBX1 protein (Fig. 4 H) .
Tbx1 regulates VEGFR3 in ECs
Of the three most highly up-regulated genes, IGF1, VEGFD, and PDPN, only Pdpn loss of function in mice is associated with lymphatic defects, namely lymphatic vessel dilatation and impaired lymphatic transport (Schacht et al., 2003) , which is unlike the lymphatic phenotype of Tbx1-null mutants. In addition, anti-VEGFD immunostaining in Tbx1-null mutants was normal. Specifically, it was expressed in LECs lining the jugular generated transgenic embryos carrying In 11-12TBE with the TBE mutated. We obtained 11 transgenic embryos with the mutant transgene (In 11-12TBE mut-lacZ) at E15.5, of which five were -gal + . In these embryos, no -gal-expressing cells were seen in Vegfr3 + mesenteric LECs (Fig. 5 , D-E) or in skin or heart lymphatic vessels (not depicted), indicating that the mutated transgene was not activated in these cells. These results demonstrate that In 11-12TBE functions as an LEC enhancer in vivo and that its activity depends on its TBE. In transgenic embryos carrying the wild-type or mutated TBE, we observed strong X-gal staining in ECs of the mesenteric artery (Fig. 5, D-E) . Vegfr3 is not normally expressed in arterial ECs at this stage, suggesting that the endogenous Vegfr3 gene harbors a suppressor element that is absent in the transgene.
In summary, our data show that Tbx1 is required in ECs for development of the GI lymphatic vasculature. In mice, the loss of this population of lymphatic vessels is lethal after birth. Elsewhere, lymphatic vessels develop in both Tie2-Cre; Tbx1 flox/lacz mutants and in Tbx1 germline-null mutants, although in the tissues surveyed, they were much reduced in number and abnormal.
(see Materials and methods) made this enhancer unresponsive to Tbx1 (Fig. 5 B) , demonstrating that its activation is mediated by this TBE.
We next determined whether this TBE is occupied by endogenous TBX1 using chromatin immunoprecipitation (ChIP) from HUVECs, which express endogenous TBX1 and VEGFR3. DNA fragments precipitated by anti-TBX1 were purified and tested for the presence of the aforementioned TBE by PCR. Results showed enrichment of DNA fragments containing the TBE in the ChIP sample (Fig. 5 C) , indicating that TBX1 occupies this site in these cells.
Next, to test whether In 11-12TBE functions as an LEC enhancer in vivo, we generated transient transgenic mice carrying an HSP-lacZ reporter driven by In 11-12TBE with either the wildtype or mutated TBE (see Materials and methods). We obtained 10 transgenic embryos with the wild-type transgene (In wtlacZ) at E15.5, of which five were -gal + . In these embryos, -gal-expressing cells colocalized with anti-Vegfr3 in LECs of the mesenteric lymphatic vessels (Fig. 5, D and E) and in lymphatic vessels of the skin and heart (not depicted). We also being developed as anticancer agents. It would be interesting to investigate whether VEGFR3 expression in the vicinity of solid tumors is regulated by TBX1.
Materials and methods
Mouse lines
The following mouse lines were used: Tbx1 lacz/+ (Lindsay et al., 2001 ), Tbx1 flox/+ (Xu et al., 2004) , Tie2Cre (Kisanuki et al., 2001) , R26R (Soriano, 1999) , TgCAGG-CreER TM (Hayashi and McMahon, 2002) , Tbx1 E5/+ (Xu et al., 2004) , and Tbx1 Cre/+ (Huynh et al., 2007) . Genotyping was performed according to the aforementioned original reports. Activation of CAGG-CreER TM was performed with a single intraperitoneal injection of 75 mg/kg body weight TM (Xu et al., 2005) .
X-gal staining, immunostaining, and immunocytofluorescence -Gal activity was revealed on 4% PFA-fixed samples by X-gal staining. Samples were photographed directly or paraffin embedded and sectioned at 10 µm. Immunostaining and immunocytofluorescence were performed using the following antibodies: rat anti-Vegfr3 (eBioscience), rat anti-PECAM-1 (BD), rabbit anti-Lyve1 (Abcam), monoclonal anti-VEGFD (R&D Systems), and rabbit anti-IGF1 (Santa Cruz Biotechnology, Inc.). Nonfluorescent antibodies were visualized after mounting slides in Cytoseal (Thermo Fisher Scientific). Fluorescent antibodies were visualized using imaging medium (Vectashield; Vector Laboratories). Whole-mount specimens were photographed using a dissecting microscope (Stemi 2000; Carl Zeiss, Inc.) equipped with a camera (Axiocam; Carl Zeiss, Inc.) and the manufacturer's acquisition software. Images of histological sections were acquired using a microscope (Axioskop 40; Carl Zeiss, Inc.) equipped with a camera (Axiocam; Carl Zeiss, Inc.) and the manufacturer's acquisition software. Photoshop (Adobe) was used for trimming and labeling images.
Cell manipulations
HUVECs (Lonza) were electroporated with increasing amounts of a TBX1 expression or with empty vector and an EGFP reporter to monitor transfection. Transfection of a standard amount of DNA in all samples was achieved by adjusting the quantity of empty vector in the mix. After 24 h, cells were fixed in 4% PFA for immunocytofluorescence or lysed for RNA isolation. qRT-PCR was performed using commercial primers (RT 2 Profiler PCR Array; PAHS-024; human angiogenesis; QIAGEN).
RNA interference was performed using commercial siRNA for TBX1 (ON-TARGETplus SMARTpool; Thermo Fisher Scientific) and a control siRNA (Thermo Fisher Scientific). HUVECs or HMLECs were transfected with 40 nM siRNA and Lipofectamine 2000 (Invitrogen). TBX1 mRNA was evaluated by qRT-PCR, and TBX1 protein was evaluated by Western blotting with anti-Tbx1 (Invitrogen). Protein levels were normalized to anti--actin (Sigma-Aldrich).
Enhancer activity assays For the luciferase construct, a 1.1-kb of DNA surrounding a conserved TBE in the Vegfr3 intron 11-12 was PCR amplified with primers 5-CGAGACT-GGAAGGAGGTGACC-3 and 5-CACCAGCTTGCTCACCGTC-3. The amplicon, named In , was first cloned into a T-vector, pCRII-TOPO (Invitrogen), and after KpnI-XhoI digestion, it was subcloned into a pGL3 luciferase expression vector (Promega). Subsequently, the enhancer fragment was subjected to site-directed mutagenesis of the TBE. The native sequence 5-TACACACCTCCA-3 was mutated to 5-TACGGGCCTCCA-3 using a site-directed mutagenesis kit (QuikChange XL; Agilent Technologies). A Tbx1 expression vector was cotransfected with the enhancer reporter (wild type or mutated) into JEG3 cells, which were harvested 48 h later. JEG3 cells transfected with empty expression vector, and without the enhancer reporter, constituted the control sample. Experiments were performed in triplicate and repeated twice.
In wt-HSPlacZ and In mut-HSPlacZ transgenes were injected into FVB/NCr pronuclei. Embryos were harvested at E15.5, stained with X-gal, and genotyped by PCR with the following primers: TT_LaczF, 5-CTGGAATTCCGCCGATACT-3; TT_LaczR, 5-CCGGATTGAT-GGTAGTGGTC-3; TT_VR3F, 5-GCCTCTGTTCTGGGTAGACG-3; and TT_VR3R, 5-AGTGCTGCCTCTGACCTCAT-3.
ChIP
ChIP experiments were performed as described previously (Breiling et al., 2004) . Chromatin from cross-linked HUVECs cells was immunoprecipitated Thus, Tbx1 is not essential for lymphangiogenesis per se; rather, it is required for the development of the lymphatic network. We have gained insights into when and how Tbx1 functions in mesenteric lymphatic development. On a Tbx1-null background, lymphatic vessels form at the appropriate time, but they are highly disorganized and fail to extend distally. Between E15.5 and E16.5, these abnormal lymphatic vessels are lost, most likely as a result of cell death. This suggests that Tbx1 has at least two roles in the mesentery. First, it is required for growth and expansion of the lymphatic network. This is consistent with our data from cultured LECs that show increased cell proliferation in response to Tbx1 transfection. Second, it is required to maintain mesenteric lymphatic vessels.
In a search for potential effectors of these functions, we found that the expression of Vegfr3 is not maintained in Tbx1 Our data support the hypothesis that, in the absence of Tbx1, lymphatic vessels are not maintained, secondary to a failure to maintain Vegfr3 expression LECs. This hypothesis is consistent with in vitro and in vivo studies that have shown a critical role for VEGF-C/Vegfr3 signaling in the growth, migration, and survival of LECs (Mäkinen et al., 2001a,b; Veikkola et al., 2001) .
Could loss of Vegfr3 in Tbx1-null ECs account for the entire lymphatic phenotype of Tbx1-null mutants? In the future, it will be interesting to see whether forced expression of Vegfr3 in ECs rescues lymphatic defects in Tbx1 mutants.
How is Tbx1 regulated? There is very little information to date. A Forkhead (Fox) transcription factor-responsive element has been identified upstream of the Tbx1 gene (Yamagishi et al., 2003) . The enhancer responds in tissue culture to Foxc2, which has also been involved in lymphatic development (for review see Tammela et al., 2005) . However, it is unknown whether Foxc2 is required for Tbx1 expression in endothelium, and, in any case, the phenotypes resulting from Tbx1 and Foxc1 or Foxc2 loss of function are different. In particular, Foxc1/2 has a later role in lymphangiogenesis compared with Tbx1 (Norrmén et al., 2009) .
TBX1 mutations can cause DiGeorge syndrome, but lymphatic defects have not been reported as part of the clinical spectrum associated with this disease. As the human disease is caused by heterozygous mutations, it is possible that a single copy of TBX1 is sufficient to support normal lymphatic vessels. Alternatively, the defects may be subclinical. Our findings should stimulate the search for subtle defects in patients. Possible consequences of mild lymphatic abnormalities in the GI tract may be reduced absorption of lipids and resulting growth delay, a common finding in affected infants (Ryan et al., 1997; Scambler, 2000; Emanuel et al., 2001) . Another question raised by this study is whether TBX1 plays a role in cancer. Many studies have linked tumor lymphangiogenesis to the development of lymph node metastases, and VEGFR3 inhibitors are currently Online supplemental material Fig. S1 shows Lyve1 immunostaining of E18.5 GI tracts of Tbx1 mutants. Fig. S2 shows that Tbx1 is expressed in and is required for development of lymphatic vessels of the heart, diaphragm, and skin. Fig. S3 shows that a lymphatic phenotype after time-controlled Tbx1 mutagenesis increased apoptosis in the proximal mesentery of Tbx1-null mutants. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200912037/DC1.
